Technical analysis of Metagenomi, Inc. Common Stock (MGX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Price Performance
| 1 month | -4.96% |
| 3 months | -4.17% |
| Year-to-date | -29.01% |
| 1 year | -38.83% |
52-Week Range
| 52-week High | $3.95 |
| 52-week Low | $1.13 |
| Avg Volume (90d) | 170K |
Technical Indicators
| SMA 50 | $1.21 |
| SMA 200 | $1.41 |
| Beta | 0.57 |
| 30-day Volatility (annualised) | 21.9% |
| Price vs SMA 50 | -5.3% |
| Price vs SMA 200 | -18.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.54 | |
| 2025-11 | $1.75 | -31.1% |
| 2025-12 | $1.62 | -7.4% |
| 2026-01 | $1.54 | -4.9% |
| 2026-02 | $1.52 | -1.3% |
| 2026-03 | $1.34 | -11.8% |
| 2026-04 | $1.38 | +3.0% |
| 2026-05 | $1.36 | -1.4% |
| 2026-06 | $1.19 | -12.5% |
| 2026-07 | $1.19 | +0.0% |
| 2026-08 | $1.18 | -0.8% |
| 2026-09 | $1.15 | -2.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $1.15 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.38 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.34 |
| Current Ratio | 4.50 |